HIGHLIGHTS
Hims AND Hers both hit all-time-high weekly web traffic in the same week (week ending May 17) 🤯
Hims has reclaimed the web traffic lead from Ro, and is now growing faster y/y (+27% vs +19%)
Hers iOS app just posted its best-ever weekly rank in the app store (#11) 🔥
Hers continues to outrank Hims, full stop -- ahead on both the latest week (#11 vs #19) and the 30-day average (#13 vs #21)
Every telehealth app we track climbed this week: Hims, Hers, Ro, and One Medical all improved, and even cellar-dweller LifeMD bounced 30 spots (#195 → #165) though still >100 spots below the rest
Y/y sales now positive 3 of the last 4 weeks. Paired with the strong web traffic + app rankings, it looks like the long-awaited “reacceleration” might finally be here
Hims Meta ads pivoted hard back to !@#$; Hers is leaning into weight loss (now well over half its ads)
“ Hims is a flop” “ Hims is going back to 16” is what everyone was saying a month ago and while it was taking a beating. Happy to see that the company has proved them wrong.
Continuous growth and continuous development since then. Props to all those that didn’t sell and held conviction!
News: Hims & Hers launches generics for Novo’s semaglutide in Canada
Corgen
prieš 2 savaites
Bad news and PERCIEVED bad news
So I have been trying to answer the question:
What are the real bad news
and what are just "feels bad" news
The bad thing is that the "feel bad" will win in short term and do fine in long term provided that good news follow.
The problem now is that all these recent news kinda throw Hims into a stagnation / falling price action. That fact will feed itself back and it will not fly up unless some really good news come which I don't see will happen for a while.
Short term bad news will move the price fast.
The long-term proposition is now little less sure in my eyes because any more bad news now will send the stock into free fall.
As this is only a 10% of my portfolio, I will be leaving this stock as it is and not add more.
Will see what happens for the next 3 months before another earnings report.
If price should start recovering, I will return to this and start thinking about buying more.
I am just not certain atm about short term price movements.
Any well reasoned prognoses from long-term investors in here?
As much as I like HIMS, this is such a bad management move. The convertible loans will dilute share holders and share earnings. Furthermore, they previously said they would fund the eucalyptus acquisition through a strong cash balance. So are we just going to pretend they didn’t change their narrative? This company went from 0 debt and a good cash flow to now expanding rapidly whilst margins have depleted and other players are aggressively entering the space.
If they had the same organic growth they had a year ago, this expansion would be justified. But the board of members are selling their shares and now deciding to spend 300 million diluting share holders whilst they spent more on buy backs at twice the current price. Management is absolutely terrible.
They need to spend on better social media marketing and a better user experience because the website sucks (doesn’t allow you to browse products and instantly wants all your details before you can even check what the products are) and so does their social media platforms, sterile and always the same vague basic posts. They’re just spending on irrelevant things it seems.
Corgen
prieš 3 savaites
Earnings - my first digestion stage
After digesting the earnings
After seeing the whole market drop today and Hims pretty much flat...
I am beginning to feel more secure in the mid to long-term.
Was aiming to add at $24 after earnings and it hasn't fallen there again yet.
Started acquiring 3x longs which fell 48% and I managed to but at -40% so I am 8% down.
Will be adding on previous dip points.
Always keeping enough cash to buy and average down massively if "tihs" (read bcckwards) hits the fan.
Keeping my position at 10% so the 90% can very well average down my long position in the worst case scenario.
This way my gains if price recovers are starting at 10% but I can add on the way up as well so effectively keeping my long in safety. Not gonna try to buy with 100% and hope to hit the bottom. Never works.
Šiame puslapyje gali būti bendruomenės sukurto turinio, už kurį „Trading 212“ neatsako. Visada atlik savo tyrimą. „Trading 212“ teikia tik vykdymo paslaugą, bet neteikia investavimo konsultacijų ar portfelio valdymo paslaugų.
Turto kaupimas – įprotis. Automatizuokite jį naudodami Pies.
Investuok į paruoštus arba susikurk savo investicijų rinkinius, pasirinkdamas iš daugybės vertybinių popierių ir ETF
Sužinok daugiau
Sužinok daugiau
Žiūrėti vaizdo įrašą
Turėk net brangiausių akcijų, tokių kaip „Google“, „Amazon“ ir „Apple“
Žiūrėti vaizdo įrašą
„Euronext“ Paryžius
NYSE, NASDAQ
Xetra, Gettex
Euronext Amsterdam
Bolsa de Madrid
Wiener Börse
Londono vertybinių popierių birža
„Euronext Lisbon“
„Euronext“ Paryžius
NYSE, NASDAQ
Xetra, Gettex
Euronext Amsterdam
Bolsa de Madrid
Wiener Börse
Londono vertybinių popierių birža
„Euronext Lisbon“
Peržiūrėk visas prekybos priemones
Pagalba visą parą
29 sekundžių vidutinis atsako laikas
Pradėk kaupti turtą jau dabar
Prisijunk prie daugiau nei 5 mln. naudotojų
Atsisiųsti programėlę
Atidaryti sąskaitą
Atsisiųsk mobiliąją programėlę
Visi pateikti statistiniai duomenys yra globalūs. Klientų skaičius atspindi finansuotas sąskaitas.
Puiku
Įvertinta 4,6/5, remiantis 93 567 atsiliepimais apie
Trustpilot
Įvertinta 4,6/5, remiantis 93 567 atsiliepimais apie
Trustpilot
Pakviestas
Great
Immediate updates, easy to use and manage.
Pakviestas
Very easy to use
Very easy to use. Intuitive app and makes it straight forward to sit back and let your investment's do its work
Pakviestas
Ease of use
Easy to set up an account
Easy to transfer funds
Great interest rate
Great all round experience
Pakviestas
Easy to set up my account
Easy to set up my account easy to access balance and a very good rate in interest.
Pakviestas
easy to use platform
easy to use platform, love the ability to transfer cash isa funds into stocks and shares isa
Pakviestas
Simple and Informative platform
I wanted a platform which was offering great rates for my ISA, but discovered not only did this platform do that. It also gave me an insight into trading and world markets. It's quite simply brilliant.
Pakviestas
Great app that provides all my account…
Great app that provides all my account info at my fingertips
Pakviestas
Easy to use.
Easy to use.
Can view everything simply.
Just what I need.
Pakviestas
Good interest rate and can take the…
Good interest rate and can take the money out whenever I want.
Pakviestas
So easy
So easy! Makes investing a pleasure
Pakviestas
I’m novice and useless with technology…
I’m novice and useless with technology but I found this an easy site to navigate and to deal with.
Pakviestas
Nice app
Great app, very intuitive and simple to use. Gold standard.
Pakviestas
Very easy to use
Very easy to use. Very clear. And a joy to watch my savings rise
Pakviestas
Easy to use
Functional and easy to use and track my cash & stocks & shares isas
Pakviestas
Easy access to my account and how Easy…
Easy access to my account and how Easy it is to navigate the212 application.
Pakviestas
Simple and easy to use app
Simple and easy to use app. Ease of setting up recurring payments. Great for a beginner that has no prior knowledge or experience of investing.
Pakviestas
Easy and simple app
Easy and simple app, tells you daily your interest which I like and I get emails. The updating is really good.
Pakviestas
Very easy and highly recommend
Very easy and highly recommend. Straight forward to use and cost instructions on the fees and charges.
Pakviestas
Great way for your money to build
Just very pleased with the level of savings rate and steady build up.
Pakviestas
Cool app
User friendly mobile app that makes investing easy and funny. Fast navigation throughout the app. In a few clicks can see basically every information one might require.
Pateikiami keli teigiami mūsų klientų atsiliepimai
Mūsų apdovanojimai
Dažniausiai užduodami klausimai
Kokia yra Hims & Hers Health (HIMS) akcijos kaina?
Dabartinė Hims & Hers Health (HIMS) kaina yra 28,82 $.
Koks yra HIMS52 savaičių maksimumas?
52 savaičių maksimumas HIMS yra 70,46 $.
Koks yra HIMS 52 savaičių žemiausias lygis?
52 savaičių žemiausias HIMS kursas yra 13,72 $.
Koks yra HIMS savaitės rezultatas?
Per pastarąją savaitę HIMS kaina pasikeitė 13,55 %.
Koks yra HIMS mėnesio našumas?
Per pastarąjį mėnesį HIMS kaina pasikeitė 5,14 %.
Koks yra HIMS 3 mėnesių rezultatas?
Per pastaruosius tris mėnesius HIMS kaina pasikeitė 82,17 %.
Koks yra HIMS 6 mėnesių rezultatas?
Per pastaruosius šešis mėnesius HIMS kaina pasikeitė −22,26 %.
Koks yra HIMSmetinis našumas?
Per pastaruosius metus HIMS kaina pasikeitė −47,34 %.